Q13882 (PTK6_HUMAN) Reviewed, UniProtKB/Swiss-Prot
Last modified
May 1, 2013.
Version 142.
History...
Names·Attributes·General annotation·Ontologies·Alt products·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize order
Names·Attributes·General annotation·Ontologies·Alt products·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize orderNames and origin
| Protein names | Recommended name: Protein-tyrosine kinase 6 EC=2.7.10.2 Alternative name(s): Breast tumor kinase Tyrosine-protein kinase BRK | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) [Reference proteome] | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo![]() |
Protein attributes
| Sequence length | 451 AA. |
| Sequence status | Complete. |
| Protein existence | Evidence at protein level |
General annotation (Comments)
| Function | Non-receptor tyrosine-protein kinase implicated in the regulation of a variety of signaling pathways that control the differentiation and maintenance of normal epithelia, as well as tumor growth. Function seems to be context dependent and differ depending on cell type, as well as its intracellular localization. A number of potential nuclear and cytoplasmic substrates have been identified. These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1, KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B and a variety of signaling molecules: ARHGAP35/p190RhoGAP, PXN/paxillin, BTK/ATK, STAP2/BKS. Associates also with a variety of proteins that are likely upstream of PTK6 in various signaling pathways, or for which PTK6 may play an adapter-like role. These proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal or non-tumorigenic tissues, PTK6 promotes cellular differentiation and apoptosis. In tumors PTK6 contributes to cancer progression by sensitizing cells to mitogenic signals and enhancing proliferation, anchorage-independent survival and migration/invasion. Association with EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and growth through enhancement of EGF-induced signaling via BTK/AKT and PI3 kinase. Contributes to migration and proliferation by contributing to EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes association with RASA1/p120RasGAP, inactivating RhoA while activating RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation. Nuclear PTK6 may be important for regulating growth in normal epithelia, while cytoplasmic PTK6 might activate oncogenic signaling pathways. Ref.9 Ref.13 Ref.14 Ref.16 Ref.18 Ref.21 Ref.23 Ref.24 Ref.31 Isoform 2 inhibits PTK6 phosphorylation and PTK6 association with other tyrosine-phosphorylated proteins. Ref.9 Ref.13 Ref.14 Ref.16 Ref.18 Ref.21 Ref.23 Ref.24 Ref.31 |
| Catalytic activity | ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. |
| Enzyme regulation | Activated by EGF, NRG1 and IGF1. Inhibited by SOCS3 to phosphorylate STAT3. Stabilized in the inactive form by an association between the SH3 domain and the SH2-TK linker region. Interaction between Trp-184 within SH2-TK linker region and the catalytic domain appears essential for positive regulation of kinase activity. Ref.11 Ref.17 Ref.19 Ref.21 Ref.22 |
| Subunit structure | Interacts with GAP-A.p65 By similarity. Interacts (via SH3 and SH2 domains) with KHDRBS1. Interacts (via SH3 and SH2 domains) with phosphorylated IRS4. Interacts with ADAM15. Interacts (via SH3 domain) with SFPQ. Interacts with EGFR and ERBB2. Interacts with STAP2. Interacts with PNX. Interacts with SFPQ. Interacts with PTK/ATK. Interacts with CTNNB1. Ref.7 Ref.9 Ref.10 Ref.14 Ref.16 Ref.19 Ref.25 Ref.27 Ref.28 Ref.30 Ref.31 |
| Subcellular location | Cytoplasm. Nucleus. Cell projection › ruffle. Membrane By similarity. Note: Colocalizes with KHDRBS1, KHDRBS2 or KHDRBS3, within the nucleus. Nuclear localization in epithelial cells of normal prostate but cytoplasmic localization in cancer prostate. Ref.10 Ref.12 Ref.13 Ref.14 Ref.15 Ref.20 |
| Tissue specificity | Epithelia-specific. Very high level in colon and high levels in small intestine and prostate, and low levels in some fetal tissues. Not expressed in breast or ovarian tissue but expressed in high percentage of breast and ovarian cancers. Also overexpressed in some metastatic melanomas, lymphomas, colon cancers, squamous cell carcinomas and prostate cancers. Also found in melanocytes. Not expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Isoform 2 is present in prostate epithelial cell lines derived from normal prostate and prostate adenocarcinomas, as well as in a variety of cell lines. Ref.8 Ref.12 Ref.15 Ref.20 |
| Domain | The SH3 domain plays a major role in substrate interactions. The SH2 domain of PTK6 plays a role in protein-protein interactions, but is likely more important for the regulation of catalytic activity. |
| Post-translational modification | Autophosphorylated. Autophosphorylation of Tyr-342 leads to an increase of kinase activity. Tyr-447 binds to the SH2 domain when phosphorylated and negatively regulates kinase activity. Ref.11 Ref.13 Ref.30 |
| Sequence similarities | Belongs to the protein kinase superfamily. Tyr protein kinase family. BRK/PTK6/SIK subfamily. Contains 1 protein kinase domain. Contains 1 SH2 domain. Contains 1 SH3 domain. |
| Biophysicochemical properties | Kinetic parameters: KM=83 µM for ATP Ref.11 Vmax=37 nmol/min/mg enzyme |
| Sequence caution | The sequence BAG62908.1 differs from that shown. Reason: Erroneous translation. Wrong choice of CDS. |
Ontologies
Alternative products
| This entry describes 2 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform 1 (identifier: Q13882-1) This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform 2 (identifier: Q13882-2) Also known as: ALT-PTK6; deltam5; The sequence of this isoform differs from the canonical sequence as follows: 78-134: WFFGCISRSE...RHYKIWRRAG → AGHAGCAALQ...AGRALPEARA 135-451: Missing. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||||||||||||||||||||||||||||||||
Molecule processing | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 451 | 451 | Protein-tyrosine kinase 6 | PRO_0000088133 | |||||||||||||||||||||||||||||||||||
Regions | |||||||||||||||||||||||||||||||||||||||
| Domain | 11 – 72 | 62 | SH3 | ||||||||||||||||||||||||||||||||||||
| Domain | 78 – 170 | 93 | SH2 | ||||||||||||||||||||||||||||||||||||
| Domain | 191 – 445 | 255 | Protein kinase | ||||||||||||||||||||||||||||||||||||
| Nucleotide binding | 197 – 205 | 9 | ATP By similarity | ||||||||||||||||||||||||||||||||||||
| Region | 171 – 190 | 20 | Linker | ||||||||||||||||||||||||||||||||||||
Sites | |||||||||||||||||||||||||||||||||||||||
| Active site | 312 | 1 | Proton acceptor By similarity | ||||||||||||||||||||||||||||||||||||
| Binding site | 219 | 1 | ATP By similarity | ||||||||||||||||||||||||||||||||||||
Amino acid modifications | |||||||||||||||||||||||||||||||||||||||
| Modified residue | 13 | 1 | Phosphotyrosine; by autocatalysis | ||||||||||||||||||||||||||||||||||||
| Modified residue | 61 | 1 | Phosphotyrosine; by autocatalysis | ||||||||||||||||||||||||||||||||||||
| Modified residue | 66 | 1 | Phosphotyrosine; by autocatalysis | ||||||||||||||||||||||||||||||||||||
| Modified residue | 114 | 1 | Phosphotyrosine; by autocatalysis Ref.26 | ||||||||||||||||||||||||||||||||||||
| Modified residue | 342 | 1 | Phosphotyrosine; by autocatalysis | ||||||||||||||||||||||||||||||||||||
| Modified residue | 351 | 1 | Phosphotyrosine; by autocatalysis | ||||||||||||||||||||||||||||||||||||
| Modified residue | 447 | 1 | Phosphotyrosine | ||||||||||||||||||||||||||||||||||||
Natural variations | |||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 78 – 134 | 57 | WFFGC…WRRAG → AGHAGCAALQDLAACRGPAA PERGGVLPQPARACELPQGP EPVPRPAAGRALPEARA in isoform 2. | VSP_042066 | |||||||||||||||||||||||||||||||||||
| Alternative sequence | 135 – 451 | 317 | Missing in isoform 2. | VSP_042067 | |||||||||||||||||||||||||||||||||||
| Natural variant | 16 | 1 | L → F in a renal papillary sample; somatic mutation. Ref.33 | VAR_041760 | |||||||||||||||||||||||||||||||||||
| Natural variant | 436 | 1 | A → T. Ref.33 Corresponds to variant rs56145017 [ dbSNP | Ensembl ]. | VAR_041761 | |||||||||||||||||||||||||||||||||||
Experimental info | |||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 44 | 1 | W → A: Strong decrease in STAP2 phosphorylation. Markedly decreased interaction between SH3 domain the linker region. Ref.9 Ref.22 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 66 | 1 | Y → A: Decrease in STAP2 phosphorylation. Ref.9 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 105 | 1 | R → L: Decrease in STAP2 phosphorylation. Ref.9 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 184 | 1 | W → A: Abrogates interaction between PTK6-domain kinase and PTK6-linker. Abrogates autophosphorylation and phosphorylation of KHDRBS1. Ref.17 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 219 | 1 | K → M: Abolishes kinase activity and cell transformation, and phosphorylation of STAP2. Ref.7 Ref.9 Ref.13 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 342 | 1 | Y → A: 3-fold lower specific kinase activity. Decrease, but still significant, autophosphorylation. Decrease, but still significant, autophosphorylation; when associated to A-447. Ref.11 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 447 | 1 | Y → F: Decrease in transforming potential and increase in the kinase activity level. Decrease, but still significant, autophosphorylation; when associated to A-342. Ref.7 Ref.11 Ref.13 | ||||||||||||||||||||||||||||||||||||
Secondary structure | |||||||||||||||||||||||||||||||||||||||
Helix Strand Turn | |||||||||||||||||||||||||||||||||||||||
| Beta strand | 12 – 14 | 3 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 35 – 40 | 6 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 45 – 50 | 6 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 56 – 62 | 7 | |||||||||||||||||||||||||||||||||||||
| Turn | 64 – 66 | 3 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 67 – 70 | 4 | |||||||||||||||||||||||||||||||||||||
| Helix | 85 – 92 | 8 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 102 – 106 | 5 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 108 – 112 | 5 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 114 – 118 | 5 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 125 – 131 | 7 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 133 – 135 | 3 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 137 – 140 | 4 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 143 – 147 | 5 | |||||||||||||||||||||||||||||||||||||
| Helix | 148 – 157 | 10 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 162 – 164 | 3 | |||||||||||||||||||||||||||||||||||||
Sequences
| ||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours." Mitchell P.J., Barker K.T., Martindale J.E., Kamalati T., Lowe P.N., Page M.J., Gusterson B.A., Crompton M.R. Oncogene 9:2383-2390(1994) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). Tissue: Mammary tumor. |
| [2] | "Characterisation and chromosome mapping of the human non receptor tyrosine kinase gene, brk." Mitchell P.J., Barker K.T., Shipley J., Crompton M.R. Oncogene 15:1497-1502(1997) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). |
| [3] | "Exon-intron structure of the human PTK6 gene demonstrates that PTK6 constitutes a distinct family of non-receptor tyrosine kinase." Lee H.-Y., Kim M., Lee K.-H., Kang K.-N., Lee S.-T. Mol. Cells 8:401-407(1998) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). Tissue: Melanocyte. |
| [4] | "Complete sequencing and characterization of 21,243 full-length human cDNAs." Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S. Sugano S.Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). Tissue: Urinary bladder. |
| [5] | "The DNA sequence and comparative analysis of human chromosome 20." Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., Bird C.P., Blakey S.E. Rogers J.Nature 414:865-871(2001) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. |
| [6] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). Tissue: Blood. |
| [7] | "Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor." Kamalati T., Jolin H.E., Mitchell P.J., Barker K.T., Jackson L.E., Dean C.J., Page M.J., Gusterson B.A., Crompton M.R. J. Biol. Chem. 271:30956-30963(1996) [PubMed] [Europe PMC] [Abstract] Cited for: CHARACTERIZATION, INTERACTION WITH EGFR, MUTAGENESIS OF LYS-219 AND TYR-447. |
| [8] | "Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma." Easty D.J., Mitchell P.J., Patel K., Florenes V.A., Spritz R.A., Bennett D.C. Int. J. Cancer 71:1061-1065(1997) [PubMed] [Europe PMC] [Abstract] Cited for: TISSUE SPECIFICITY. |
| [9] | "A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK." Mitchell P.J., Sara E.A., Crompton M.R. Oncogene 19:4273-4282(2000) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION, INTERACTION WITH STAP2, MUTAGENESIS OF TRP-44; TYR-66; ARG-105 AND LYS-219. |
| [10] | "Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability." Derry J.J., Richard S., Valderrama Carvajal H., Ye X., Vasioukhin V., Cochrane A.W., Chen T., Tyner A.L. Mol. Cell. Biol. 20:6114-6126(2000) [PubMed] [Europe PMC] [Abstract] Cited for: SUBCELLULAR LOCATION, INTERACTION WITH KHDRBS1. |
| [11] | "Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition." Qiu H., Miller W.T. J. Biol. Chem. 277:34634-34641(2002) [PubMed] [Europe PMC] [Abstract] Cited for: AUTOPHOSPHORYLATION, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF TYR-342 AND TYR-447, ENZYME REGULATION, MASS SPECTROMETRY. |
| [12] | "Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells." Derry J.J., Prins G.S., Ray V., Tyner A.L. Oncogene 22:4212-4220(2003) [PubMed] [Europe PMC] [Abstract] Cited for: SUBCELLULAR LOCATION, TISSUE SPECIFICITY. |
| [13] | "The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2." Haegebarth A., Heap D., Bie W., Derry J.J., Richard S., Tyner A.L. J. Biol. Chem. 279:54398-54404(2004) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-219 AND TYR-447, PHOSPHORYLATION. |
| [14] | "Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin." Chen H.Y., Shen C.H., Tsai Y.T., Lin F.C., Huang Y.P., Chen R.H. Mol. Cell. Biol. 24:10558-10572(2004) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION IN CELL MIGRATION, FUNCTION IN PHOSPHORYLATION OF PXN, SUBCELLULAR LOCATION, INTERACTION WITH PXN. |
| [15] | "Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium." Petro B.J., Tan R.C., Tyner A.L., Lingen M.W., Watanabe K. Oral Oncol. 40:1040-1047(2004) [PubMed] [Europe PMC] [Abstract] Cited for: TISSUE SPECIFICITY, SUBCELLULAR LOCATION. |
| [16] | "Regulated association of protein kinase B/Akt with breast tumor kinase." Zhang P., Ostrander J.H., Faivre E.J., Olsen A., Fitzsimmons D., Lange C.A. J. Biol. Chem. 280:1982-1991(2005) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION IN PHOSPHORYLATION OF BTK, INTERACTION WITH BTK. |
| [17] | "An intramolecular interaction between SH2-kinase linker and kinase domain is essential for the catalytic activity of protein-tyrosine kinase-6." Kim H.I.E., Lee S.T. J. Biol. Chem. 280:28973-28980(2005) [PubMed] [Europe PMC] [Abstract] Cited for: MUTAGENESIS OF TRP-184, ENZYME REGULATION. |
| [18] | "Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression." Lukong K.E., Larocque D., Tyner A.L., Richard S. J. Biol. Chem. 280:38639-38647(2005) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION IN PHOSPHORYLATION OF KHDRBS1. |
| [19] | "Interaction between Brk kinase and insulin receptor substrate-4." Qiu H., Zappacosta F., Su W., Annan R.S., Miller W.T. Oncogene 24:5656-5664(2005) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH IRS4, ENZYME REGULATION. |
| [20] | "Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes." Kasprzycka M., Majewski M., Wang Z.J., Ptasznik A., Wysocka M., Zhang Q., Marzec M., Gimotty P., Crompton M.R., Wasik M.A. Am. J. Pathol. 168:1631-1641(2006) [PubMed] [Europe PMC] [Abstract] Cited for: TISSUE SPECIFICITY, SUBCELLULAR LOCATION. |
| [21] | "Identification of STAT3 as a specific substrate of breast tumor kinase." Liu L., Gao Y., Qiu H., Miller W.T., Poli V., Reich N.C. Oncogene 25:4904-4912(2006) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION IN PHOSPHORYLATION OF STAT3, ENZYME REGULATION. |
| [22] | "Molecular dissection of the interaction between the SH3 domain and the SH2-Kinase Linker region in PTK6." Kim H.I.E., Jung J., Lee E.S., Kim Y.C., Lee W., Lee S.T. Biochem. Biophys. Res. Commun. 362:829-834(2007) [PubMed] [Europe PMC] [Abstract] Cited for: ENZYME REGULATION, MUTAGENESIS OF TRP-44. |
| [23] | "Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6." Weaver A.M., Silva C.M. Breast Cancer Res. 9:R79-R79(2007) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION IN PHOSPHORYLATION OF STAT5B. |
| [24] | "Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion." Shen C.H., Chen H.Y., Lin M.S., Li F.Y., Chang C.C., Kuo M.L., Settleman J., Chen R.H. Cancer Res. 68:7779-7787(2008) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION IN PHOSPHORYLATION OF ARHGAP35. |
| [25] | "Distinct functions of natural ADAM-15 cytoplasmic domain variants in human mammary carcinoma." Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M., Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C., Edwards D.R. Mol. Cancer Res. 6:383-394(2008) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH ADAM15. |
| [26] | "Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle." Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., Greff Z., Keri G., Stemmann O., Mann M. Mol. Cell 31:438-448(2008) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-114, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [27] | "Brk is coamplified with ErbB2 to promote proliferation in breast cancer." Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M., Miller W.T., Muthuswamy S.K. Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH ERBB2. |
| [28] | "BRK phosphorylates PSF promoting its cytoplasmic localization and cell cycle arrest." Lukong K.E., Huot M.E., Richard S. Cell. Signal. 21:1415-1422(2009) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH SFPQ. |
| [29] | "Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK." Brauer P.M., Tyner A.L. Biochim. Biophys. Acta 1806:66-73(2010) [PubMed] [Europe PMC] [Abstract] Cited for: REVIEW ON FUNCTION. |
| [30] | "Identification of beta-catenin as a target of the intracellular tyrosine kinase PTK6." Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y., Asara J.M., Tyner A.L. J. Cell Sci. 123:236-245(2010) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION OF CTNNB1, INTERACTION WITH CTNNB1. |
| [31] | "The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of beta-catenin." Brauer P.M., Zheng Y., Evans M.D., Dominguez-Brauer C., Peehl D.M., Tyner A.L. PLoS ONE 6:E14789-E14789(2011) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION (ISOFORM 2), INTERACTION (ISOFORM 2) WITH KHDRBS1 AND CTNNB1. |
| [32] | "Solution structure and backbone dynamics of the non-receptor protein-tyrosine kinase-6 Src homology 2 domain." Hong E., Shin J., Kim H.I., Lee S.T., Lee W. J. Biol. Chem. 279:29700-29708(2004) [PubMed] [Europe PMC] [Abstract] Cited for: STRUCTURE BY NMR OF 75-174. |
| [33] | "Patterns of somatic mutation in human cancer genomes." Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G. Stratton M.R.Nature 446:153-158(2007) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS [LARGE SCALE ANALYSIS] PHE-16 AND THR-436. |
| + | Additional computationally mapped references. |
Cross-references
Sequence databases | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMBL GenBank DDBJ | X78549 mRNA. Translation: CAA55295.1. U61412 U61411 Genomic DNA. Translation: AAC34935.1.AK315232 mRNA. Translation: BAG37660.1. AK301364 mRNA. Translation: BAG62908.1. Sequence problems. AL121829 Genomic DNA. Translation: CAC15525.1. BC035843 mRNA. Translation: AAH35843.1. | ||||||||||||||||||
| IPI | IPI00015927. | ||||||||||||||||||
| PIR | S49016. | ||||||||||||||||||
| RefSeq | NP_001243287.1. NM_001256358.1. NP_005966.1. NM_005975.3. | ||||||||||||||||||
| UniGene | Hs.51133. | ||||||||||||||||||
3D structure databases | |||||||||||||||||||
| PDBe RCSB PDB PDBj |
| ||||||||||||||||||
| ProteinModelPortal | Q13882. | ||||||||||||||||||
| ModBase | Search... | ||||||||||||||||||
Protein-protein interaction databases | |||||||||||||||||||
| DIP | DIP-39785N. | ||||||||||||||||||
| IntAct | Q13882. 1 interaction. | ||||||||||||||||||
| MINT | MINT-1494499. | ||||||||||||||||||
| STRING | 9606.ENSP00000217185. | ||||||||||||||||||
PTM databases | |||||||||||||||||||
| PhosphoSite | Q13882. | ||||||||||||||||||
Polymorphism databases | |||||||||||||||||||
| DMDM | 8928302. | ||||||||||||||||||
Proteomic databases | |||||||||||||||||||
| PaxDb | Q13882. | ||||||||||||||||||
| PRIDE | Q13882. | ||||||||||||||||||
Protocols and materials databases | |||||||||||||||||||
| DNASU | 5753. | ||||||||||||||||||
| StructuralBiologyKnowledgebase | Search... | ||||||||||||||||||
Genome annotation databases | |||||||||||||||||||
| Ensembl | ENST00000217185; ENSP00000217185; ENSG00000101213. ENST00000542869; ENSP00000442460; ENSG00000101213. | ||||||||||||||||||
| GeneID | 5753. | ||||||||||||||||||
| KEGG | hsa:5753. | ||||||||||||||||||
| UCSC | uc002yfg.3. human. | ||||||||||||||||||
Organism-specific databases | |||||||||||||||||||
| CTD | 5753. | ||||||||||||||||||
| GeneCards | GC20M062159. | ||||||||||||||||||
| HGNC | HGNC:9617. PTK6. | ||||||||||||||||||
| HPA | CAB032952. HPA036070. HPA036071. | ||||||||||||||||||
| MIM | 602004. gene. | ||||||||||||||||||
| neXtProt | NX_Q13882. | ||||||||||||||||||
| PharmGKB | PA33960. | ||||||||||||||||||
| GenAtlas | Search... | ||||||||||||||||||
Phylogenomic databases | |||||||||||||||||||
| eggNOG | COG0515. | ||||||||||||||||||
| HOGENOM | HOG000233858. | ||||||||||||||||||
| HOVERGEN | HBG008761. | ||||||||||||||||||
| InParanoid | Q13882. | ||||||||||||||||||
| KO | K08894. | ||||||||||||||||||
| OMA | VRHYKIW. | ||||||||||||||||||
| OrthoDB | EOG4NVZK9. | ||||||||||||||||||
| PhylomeDB | Q13882. | ||||||||||||||||||
Enzyme and pathway databases | |||||||||||||||||||
| BRENDA | 2.7.10.2. 2681. | ||||||||||||||||||
Gene expression databases | |||||||||||||||||||
| Bgee | Q13882. | ||||||||||||||||||
| CleanEx | HS_PTK6. | ||||||||||||||||||
| Genevestigator | Q13882. | ||||||||||||||||||
| GermOnline | ENSG00000101213. Homo sapiens. | ||||||||||||||||||
Family and domain databases | |||||||||||||||||||
| Gene3D | 3.30.505.10. 1 hit. | ||||||||||||||||||
| InterPro | IPR011009. Kinase-like_dom. IPR000719. Prot_kinase_cat_dom. IPR017441. Protein_kinase_ATP_BS. IPR001245. Ser-Thr/Tyr_kinase_cat_dom. IPR000980. SH2. IPR001452. SH3_domain. IPR008266. Tyr_kinase_AS. IPR020635. Tyr_kinase_cat_dom. [Graphical view] | ||||||||||||||||||
| Pfam | PF07714. Pkinase_Tyr. 1 hit. PF00017. SH2. 1 hit. PF00018. SH3_1. 1 hit. [Graphical view] | ||||||||||||||||||
| PRINTS | PR00401. SH2DOMAIN. PR00452. SH3DOMAIN. PR00109. TYRKINASE. | ||||||||||||||||||
| SMART | SM00252. SH2. 1 hit. SM00326. SH3. 1 hit. SM00219. TyrKc. 1 hit. [Graphical view] | ||||||||||||||||||
| SUPFAM | SSF56112. Kinase_like. 1 hit. SSF50044. SH3. 1 hit. | ||||||||||||||||||
| PROSITE | PS00107. PROTEIN_KINASE_ATP. 1 hit. PS50011. PROTEIN_KINASE_DOM. 1 hit. PS00109. PROTEIN_KINASE_TYR. 1 hit. PS50001. SH2. 1 hit. PS50002. SH3. 1 hit. [Graphical view] | ||||||||||||||||||
| ProtoNet | Search... | ||||||||||||||||||
Other | |||||||||||||||||||
| BindingDB | Q13882. | ||||||||||||||||||
| ChEMBL | CHEMBL4601. | ||||||||||||||||||
| EvolutionaryTrace | Q13882. | ||||||||||||||||||
| GenomeRNAi | 5753. | ||||||||||||||||||
| NextBio | 22386. | ||||||||||||||||||
| SOURCE | Search... | ||||||||||||||||||
Entry information
| Entry name | PTK6_HUMAN | ||||||||
| Accession | Primary (citable) accession number: Q13882 Secondary accession number(s): B2RCR3, B4DW46, Q58F01 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation program | Chordata Protein Annotation Program | ||||||||
| Disclaimer | Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. | ||||||||
Relevant documents
| Human and mouse protein kinases Human and mouse protein kinases: classification and index |
| Human chromosome 20 Human chromosome 20: entries, gene names and cross-references to MIM |
| Human entries with polymorphisms or disease mutations List of human entries with polymorphisms or disease mutations |
| Human polymorphisms and disease mutations Index of human polymorphisms and disease mutations |
| MIM cross-references Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot |
| PDB cross-references Index of Protein Data Bank (PDB) cross-references |
| SIMILARITY comments Index of protein domains and families |

Clusters with
